Compare GSK & BSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSK | BSX |
|---|---|---|
| Founded | 1715 | 1979 |
| Country | United Kingdom | United States |
| Employees | 66841 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.3B | 93.4B |
| IPO Year | N/A | 2010 |
| Metric | GSK | BSX |
|---|---|---|
| Price | $57.89 | $64.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 21 |
| Target Price | N/A | ★ $102.19 |
| AVG Volume (30 Days) | 3.9M | ★ 14.5M |
| Earning Date | 04-29-2026 | 04-22-2026 |
| Dividend Yield | ★ 2.95% | N/A |
| EPS Growth | N/A | ★ 55.20 |
| EPS | N/A | ★ 1.94 |
| Revenue | N/A | ★ $9,076,000,000.00 |
| Revenue This Year | $6.70 | $11.91 |
| Revenue Next Year | $4.22 | $10.26 |
| P/E Ratio | ★ $32.75 | $32.89 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $35.08 | $60.59 |
| 52 Week High | $61.70 | $109.50 |
| Indicator | GSK | BSX |
|---|---|---|
| Relative Strength Index (RSI) | 58.55 | 42.01 |
| Support Level | $47.89 | N/A |
| Resistance Level | $60.37 | $76.77 |
| Average True Range (ATR) | 1.03 | 1.77 |
| MACD | 0.44 | 0.42 |
| Stochastic Oscillator | 69.29 | 37.79 |
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.